Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

NCT04283669 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT04283669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04283669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 2
Overall status
Completed
Start date
February 18, 2020
Completion date
February 25, 2025
Enrollment
12 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibromatosis 2, progressive vestibular schwannoma (vs)